
BridgeBio Pharma, Inc.: updates and filings
Price
$77.36
November 16, 2026Market cap $15.0B
What Ploutos Investor adds for BridgeBio Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Feb 5, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
October 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 13, 2026Other material eventsForm8-K
- Aug 31, 2026Other material eventsForm8-K
- Aug 17, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 17, 2026Material agreement entered, other material eventsForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Aug 3, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 24, 2026Shelf registration for future offeringsFormS-3ASR
- Jul 24, 2026Shares registered for employeesFormS-8
- Jul 22, 2026Other material eventsForm8-K
- Jul 10, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 2, 2026Material agreement entered, unregistered sale of shares, change to shareholders' rights, amended articles or bylaws, Regulation FD disclosureForm8-K
- Jun 26, 2026Officer or director change, shareholder voteForm8-K
- May 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 27, 2026Other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Other material eventsForm8-K
- May 8, 2026Material agreement entered, material agreement endedForm8-K
- May 8, 2026Shelf registration for future offeringsFormS-3ASR
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 13, 2026 | 8-K | Other material events | Document |
| Aug 31, 2026 | 8-K | Other material events | Document |
| Aug 17, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 17, 2026 | 8-K | Material agreement entered, other material events | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Aug 3, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 24, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Jul 24, 2026 | S-8 | Shares registered for employees | Document |
| Jul 22, 2026 | 8-K | Other material events | Document |
| Jul 10, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 2, 2026 | 8-K | Material agreement entered, unregistered sale of shares, change to shareholders' rights, amended articles or bylaws, Regulation FD disclosure | Document |
| Jun 26, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 27, 2026 | 8-K | Other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | 8-K | Other material events | Document |
| May 8, 2026 | 8-K | Material agreement entered, material agreement ended | Document |
| May 8, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 19, 2018.
The full analysis
What do BridgeBio Pharma's filings show?
The filings are where every one of BridgeBio Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.